Patents by Inventor Eric-Paul Paques
Eric-Paul Paques has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8580771Abstract: A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.Type: GrantFiled: October 6, 2005Date of Patent: November 12, 2013Assignee: Richter Gedeon Nyrt.Inventors: Georg Schramm, Eric-Paul Paques
-
Publication number: 20120053160Abstract: A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 ?g of folic acid and the daily units B contain >200 ?g up to the maximum permissible amount of folic acid for women.Type: ApplicationFiled: November 7, 2011Publication date: March 1, 2012Applicant: Gruenenthal GmnHInventors: Georg SCHRAMM, Eric-Paul PAQUES
-
Patent number: 8119620Abstract: A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 ?g of folic acid and the daily units B contain >200 ?g up to the maximum permissible amount of folic acid for women.Type: GrantFiled: May 9, 2008Date of Patent: February 21, 2012Assignee: Gruenenthal GmbHInventors: Georg Schramm, Eric-Paul Paques
-
Publication number: 20110172197Abstract: A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.Type: ApplicationFiled: March 23, 2011Publication date: July 14, 2011Applicant: Grunenthal GmbHInventors: Georg SCHRAMM, Eric-Paul PAQUES
-
Publication number: 20090286831Abstract: A pharmaceutical composition comprising i) at least one composition that has affinity to the ?-opioid receptor, and at least one compound that has affinity to the VR1 receptor, or ii) at least one compound, in particular at least one compound corresponding to formula (I), (II), (III), (IV) or (V), that has affinity to the ?-opioid receptor and to the VR1 receptor, and also to the use of the pharmaceutical compositions i) and ii) for the production of a drug for the treatment of pain.Type: ApplicationFiled: April 17, 2009Publication date: November 19, 2009Applicant: Gruenenthal GMBHInventors: Babette-Yvonne KOEGEL, Thomas CHRISTOPH, Gregor BAHRENBERG, Robert FRANK, Wolfgang SCHROEDER, Jean DE VRY, Eric-Paul PAQUES, Derek SAUNDERS, Klaus SCHIENE, Bernd SUNDERMANN, Jeewoo LEE, Hyung-Chul RYU
-
Publication number: 20080312587Abstract: The invention relates to a system for the oral administration of a solid to dementia sufferers comprising at least two devices, in which each device comprises an optionally transparent hollow article with a liquid inlet end and a liquid outlet end, wherein a solid and a liquid-permeable, optionally displaceable retention means are arranged in the interior of the hollow article in such a manner that the retention means prevents the solid from escaping from the interior of the hollow article via the liquid inlet end.Type: ApplicationFiled: June 7, 2005Publication date: December 18, 2008Applicant: GRUENETHAL GMBHInventors: Heinrich Kugelmann, Johannes Bartholomaus, Eric-Paul Paques
-
Publication number: 20080261934Abstract: A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 ?g of folic acid and the daily units B contain >200 ?g up to the maximum permissible amount of folic acid for women.Type: ApplicationFiled: May 9, 2008Publication date: October 23, 2008Applicant: Gruenenthal GmbHInventors: Georg SCHRAMM, Eric-Paul Paques
-
Publication number: 20060089338Abstract: A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.Type: ApplicationFiled: October 6, 2005Publication date: April 27, 2006Inventors: Georg Schramm, Eric-Paul Paques
-
Publication number: 20050267083Abstract: The present invention relates to a dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, characterised in that the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.Type: ApplicationFiled: December 10, 2004Publication date: December 1, 2005Inventors: Georg Schramm, Eric-Paul Paques
-
Patent number: 6248365Abstract: The invention relates to the use of complement inhibitors, especially of C1 inactivator or of factors I or H, for the preparation of a pharmaceutical and for the prophylaxis and therapy of chronic inflammatory intestinal disorders, inflammatory skin disorders and purpura.Type: GrantFiled: July 7, 1993Date of Patent: June 19, 2001Assignee: Aventis Behring GmbHInventors: Jürgen Römisch, Eric-Paul Pâques, Robert Bartlett, Gerhard Dickneite
-
Patent number: 5976530Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.Type: GrantFiled: February 13, 1997Date of Patent: November 2, 1999Assignees: Chiron Corporation, Hoechst Marion Roussel Deutschland GmbHInventors: Nancy L. Haigwood, Guy Mullenbach, Ernst-Guenter Afting, Eric Paul Paques
-
Patent number: 5691312Abstract: Liquid pharmaceuticals for subcutaneous (sc) or intramuscular (im) administration containing a polypeptide and at least one amino acid, a process for the preparation of such a pharmaceutical and the use of an amino acid, which is suitable for sc or im administration, in a solution of a polypeptide are described.Type: GrantFiled: June 7, 1995Date of Patent: November 25, 1997Assignee: Behringwerke AktiengesellschaftInventor: Eric-Paul Paques
-
Patent number: 5656269Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, reduced fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying the C-terminus by deletions.Type: GrantFiled: January 31, 1995Date of Patent: August 12, 1997Assignees: Chiron Corp., Behringwerke AGInventors: Nancy L. Haigwood, Guy Mullenbach, Ernst-Guenter Afting, Eric Paul Paques
-
Patent number: 5439679Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.The plasmids designated 1, 2 and 3 were deposited at the A.T.C.C. on Dec. 20, 1985 and given A.T.C.C. designations 40214, 40215 and 40216, respectively.Type: GrantFiled: March 10, 1994Date of Patent: August 8, 1995Assignees: Chiron Corporation, Behringwerke AGInventors: Ernest-Guenter Afting, Eric-Paul Paques, Nancy L. Haigwood, Guy Mullenbach
-
Patent number: 5116962Abstract: A process for the preparation of a material for affinity chromatography is described, in which a sulfated polysaccharide is bonded to a carrier material which has amino groups.For this purpose, a sulfated polysaccharide is treated with an oxidizing agent which oxidizes glycols to aldehydes, with cleavage of the carbon chain, and this modified sulfated polysaccharide is allowed to react with a carrier which has amino groups.It is possible using the described affinity material to adsorb proteins which bind to sulfated polysaccharides from solutions of these proteins and, where appropriate, then to desorb them, for example antithrombin III from blood plasma.Type: GrantFiled: July 16, 1990Date of Patent: May 26, 1992Assignee: Behringwerke AktiengesellschaftInventors: Werner Stuber, Eric-Paul Paques